Skip to content
OpenCapital
Get started

aTyr Pharma ATYR Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
United Therapeutics logo
United TherapeuticsUTHR
$1.28B-32.6%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$12.77M-6.6%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$56.4M+14.3%
Vor Biopharma logo
Vor BiopharmaVOR
$169.87M+239%

Other financials

Income statement

See full
Revenue-—
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K—
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M—
P/S288.8×—

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's cash & equivalents?
aTyr Pharma (ATYR) reported cash & equivalents of $10.01M in Q1 2026.
How has aTyr Pharma's cash & equivalents changed year-over-year?
aTyr Pharma's cash & equivalents decreased by 3.4% year-over-year, from $10.36M to $10.01M.
What is the long-term trend for aTyr Pharma's cash & equivalents?
Over 5 years (2020 to 2025), aTyr Pharma's cash & equivalents has grown at a -8.7% compound annual growth rate (CAGR), from $16.95M to $10.74M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.